Health
R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program
Merck's head of R&;D Dean Li believes he’s outfoxed his competition for the next generation of oncology drugs, jumping into a wide set of indications that could help it expand the potential of its antibody-drug ...
- Published
- (1 h ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 36-word snippet. The full article is at the source.
More from Endpoints News and around the same time
For Lilly, cash-pay is key in the US and, increasingly, abroadEli Lilly already knows Americans are willing to shell out hundreds of dollars a month for obesity drugs. Its bet on selling directly to patients helped it build a substantialBristol Myers defends pipeline, reinforces later stage BD interestBristol Myers Squibb is re-emphasizing its plan to stave off one of the industry’s most daunting patent cliffs. Speaking to analysts on its earnings call on Thursday, executives at the New Jersey pharma company touted ...UK lands £500M in biopharma pledges; Teva to shutter New Jersey sitePlus, news about Esteve and Regeneron. UK pulls in £500M investment: As part of the UK’s Autumn budget, Vertex Pharmaceuticals said it will invest over £300 million in a new R&;D site in Oxford, UK ...Ono's five failures; Lenz and Molecular Partners to lay off staffPlus, news about GSK, Ascletis, BioMarin, Rigerna and Hisun. Ono Pharma’s endocannabinoid modulator flunks five trials: The biotech’s ONO-1110 did not meet the primary endpoint in five separate Phase 2 studies ...Genmab's stock rises on cancer data, while Iovance, Coherus tumbleCancer trial news drove a number of stock moves in both directions over the past 24 hours. Here's a summary of key results and their impact: Genmab shares rise on head and neck cancer data: ...Personal AI agents are coming to healthcareIn September, I reported on the phenomenon of big tech companies and startups standing up capabilities to ingest people’s medical records and other health data, so they could interpret the ...This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
